SLC5A2 and type 2 diabetes mellitus: In a pooled analysis of 14 unique randomised, placebo-controlled CVOTs of SGLT2-Is and GLP1-RAs in patients with T2D, we examined racial/ethnic and regional patterns in the effects of these agents on various cardiovascular and renal outcomes.